SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis?
Mené sur 85 patientes atteintes d'un cancer du sein ER+, HER2- de stade métastatique, cet essai de phase II évalue l'efficacité d'un bain de bouche à base de dexaméthasone pour prévenir une stomatite induite par l'évérolimus
Since the regulatory approval of tamoxifen in 1977, treatment with endocrine monotherapy, including aromatase inhibitors such as exemestane, has been the foundation of treatment for hormone receptor-positive metastatic breast cancer.1 However, in 2012, the approval of the mTOR inhibitor everolimus combined with exemestane,2 based on a randomised phase 3 study (BOLERO-2)3,4 showing that the addition of everolimus to exemestane (vs exemestane alone) extended median progression-free survival from 4·1 months to 11·0 months (log-rank p<0·0001), represented a crucial shift in the treatment landscape for hormone receptor-positive metastatic breast cancer.
The Lancet Oncology , commentaire, 2016